Spots Global Cancer Trial Database for Individualized Treatments in Adults With Relapsed/Refractory Cancers

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Individualized Treatments in Adults With Relapsed/Refractory Cancers

Official Title: Individualized Treatments in Adults With Relapsed/Refractory Cancers

Study ID: NCT06024603

Conditions

Refractory Cancer

Relapsed Cancer

Interventions

Drug Sensitivity Test (DST)

Study Description

Brief Summary: A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

Detailed Description: Treatment itself will not be given as part of this trial. The results of the drug sensitivity test (DST) and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices. The physician will decide the most appropriate treatment for each case, with the option to add one or more personalized (assay-guided) drug(s) from the investigational platform. All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available.